6 New Drugs Approved for Primary Care: Q2 2021
Another quarter has come and gone, which means Patient Care Online has compiled a list of 6 new FDA-approved drugs for conditions that are often seen in primary care. Scroll through the slides below to find details on the first and only antihistamine nasal spray for allergies available over-the-counter in the US, the first drug approved for chronic weight management since 2014, and 4 more.
Attention Deficit Hyperactivity Disorder (ADHD): Qelbree (viloxazine hydrochloride) Extended-Release Capsules, 100 mg, 150 mg, 200 mg, a selective norepinephrine reuptake inhibitor indicated for the treatment of ADHD in pediatric patients aged 6 to 17 years. (Approved 4/2/2021, Supernus Pharmaceuticals, Inc.)
For full prescribing information, please click here.
Pregnancy Prevention: Nextstellis (drospirenone and estetrol [E4]) Tablets, a novel oral contraceptive pill containing 3 mg drospirenone (a progestin) and 14.2 mg estetrol, indicated for use by women of reproductive potential to prevent pregnancy. Estetrol is an estrogen naturally produced during pregnancy that can now be made from a plant source. (Approved 4/15/2021, Mayne Pharma)
For full prescribing information, please click here.
Opioid Overdose: Kloxxado (naloxone hydrochloride) Nasal Spray, 8 mg, an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients. It is not a substitute for emergency medical care. (Approved 4/30/21, Hikma Pharmaceuticals PLC)
For full prescribing information, please click here.
Allergic Rhinitis: Astepro Allergy (azelastine hydrochloride nasal spray, 0.15%), is the first and only steroid-free, antihistamine nasal spray for allergies available over-the-counter in the US. It is indicated for the temporary relief of nasal congestion, runny nose, sneezing, and itchy nose due to allergic rhinitis or other upper respiratory allergies for adults and children aged ≥6 years. (Approved 6/17/21, Bayer Healthcare LLC)
For the product label, please click here.
Obesity: Wegovy (semaglutide 2.4 mg) Injection, is the first once-weekly glucagon-like peptide-1 receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI≥30 kg/m2) or overweight (BMI≥27 kg/m2) with at least 1 weight-related comorbidity (eg, hypertension, hyperlipidemia, type 2 diabetes). (Approved 6/4/21, Novo Nordisk)
For full prescribing information, please click here.
Pneumococcal Disease: Prevnar 20 (pneumococcal 20-valent conjugate vaccine) Injection, the first conjugate vaccine indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults aged ≥18 years. (Approved 6/8/21, Pfizer. Inc)
For full prescribing information, please click here.
For a quick review of primary care drugs approved in the first quarter of 2021, check out 6 New Drugs Approved for Primary Care: Q1 2021.
